Literature DB >> 18172852

Cortical dysfunction in patients with Huntington's disease during working memory performance.

Robert C Wolf1, Nenad Vasic, Carlos Schönfeldt-Lecuona, Daniel Ecker, Georg Bernhard Landwehrmeyer.   

Abstract

Previous functional neuroimaging studies on executive function suggested multiple functionally aberrant cortical regions in patients with Huntington's disease (HD). However, little is known about the neural mechanisms of working memory (WM) function in this patient population. The objective of this study was to investigate the functional neuroanatomy of WM in HD patients. We used event-related functional magnetic resonance imaging and a parametric verbal WM task to investigate cerebral function during WM performance in 16 healthy control subjects and 12 mild to moderate stage HD patients. We excluded incorrectly performed trials to control for potential accuracy-related activation confounds. Voxel-based morphometry (VBM) was used to control for confounding cortical and subcortical atrophy. We found that HD patients were slower and less accurate than healthy controls across all WM load levels. In addition, HD patients showed lower activation in the left dorso- and ventrolateral prefrontal cortex, the left inferior parietal cortex, the left putamen, and the right cerebellum at high WM load levels only. VBM revealed gray matter differences in the bilateral caudate nucleus and the thalamus, as well as in inferior parietal and right lateral prefrontal regions. However, volumetric abnormalities in the patient group did not affect the activation differences obtained during WM task performance. These findings demonstrate that WM-related functional abnormalities in HD patients involve distinct WM network nodes associated with cognitive control and subvocal rehearsal. Moreover, aberrant cortical function in HD patients may occur in brain regions, which are relatively well preserved in terms of brain atrophy. (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2009        PMID: 18172852      PMCID: PMC6870646          DOI: 10.1002/hbm.20502

Source DB:  PubMed          Journal:  Hum Brain Mapp        ISSN: 1065-9471            Impact factor:   5.038


  56 in total

1.  The episodic buffer: a new component of working memory?

Authors: 
Journal:  Trends Cogn Sci       Date:  2000-11-01       Impact factor: 20.229

2.  Diffusion tensor imaging in presymptomatic and early Huntington's disease: Selective white matter pathology and its relationship to clinical measures.

Authors:  H Diana Rosas; David S Tuch; Nathanael D Hevelone; Alexandra K Zaleta; Mark Vangel; Steven M Hersch; David H Salat
Journal:  Mov Disord       Date:  2006-09       Impact factor: 10.338

3.  Changes over time in frontotemporal activation during a working memory task in patients with schizophrenia.

Authors:  Robert Christian Wolf; Nenad Vasic; Annett Höse; Manfred Spitzer; Henrik Walter
Journal:  Schizophr Res       Date:  2007-01-26       Impact factor: 4.939

4.  Prefrontal cortical blood flow and cognitive function in Huntington's disease.

Authors:  D R Weinberger; K F Berman; M Iadarola; N Driesen; R F Zec
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-01       Impact factor: 10.154

5.  Enantio-selective cognitive and brain activation effects of N-ethyl-3,4-methylenedioxyamphetamine in humans.

Authors:  M Spitzer; B Franke; H Walter; J Buechler; A P Wunderlich; M Schwab; K A Kovar; L Hermle; G Grön
Journal:  Neuropharmacology       Date:  2001-08       Impact factor: 5.250

6.  Cognitive impairments in early Parkinson's disease are accompanied by reductions in activity in frontostriatal neural circuitry.

Authors:  Simon J G Lewis; Anja Dove; Trevor W Robbins; Roger A Barker; Adrian M Owen
Journal:  J Neurosci       Date:  2003-07-16       Impact factor: 6.167

7.  Cognitive changes in patients with Huntington's disease (HD) and asymptomatic carriers of the HD mutation--a longitudinal follow-up study.

Authors:  Jurgen Lemiere; Marleen Decruyenaere; Gery Evers-Kiebooms; Erik Vandenbussche; Rene Dom
Journal:  J Neurol       Date:  2004-08       Impact factor: 4.849

8.  Thalamic atrophy in Huntington's disease co-varies with cognitive performance: a morphometric MRI analysis.

Authors:  Jan Kassubek; Freimut D Juengling; Daniel Ecker; G Bernhard Landwehrmeyer
Journal:  Cereb Cortex       Date:  2004-09-30       Impact factor: 5.357

9.  Longitudinal analysis of regional grey matter loss in Huntington disease: effects of the length of the expanded CAG repeat.

Authors:  H H Ruocco; L Bonilha; L M Li; I Lopes-Cendes; F Cendes
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-07-05       Impact factor: 10.154

10.  Comparison of executive and visuospatial memory function in Huntington's disease and dementia of Alzheimer type matched for degree of dementia.

Authors:  K W Lange; B J Sahakian; N P Quinn; C D Marsden; T W Robbins
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-05       Impact factor: 10.154

View more
  22 in total

1.  Reduced expression of conditioned fear in the R6/2 mouse model of Huntington's disease is related to abnormal activity in prelimbic cortex.

Authors:  Adam G Walker; Jason R Ummel; George V Rebec
Journal:  Neurobiol Dis       Date:  2011-04-16       Impact factor: 5.996

2.  "Frontal" behaviors before the diagnosis of Huntington's disease and their relationship to markers of disease progression: evidence of early lack of awareness.

Authors:  Kevin Duff; Jane S Paulsen; Leigh J Beglinger; Douglas R Langbehn; Chiachi Wang; Julie C Stout; Christopher A Ross; Elizabeth Aylward; Noelle E Carlozzi; Sarah Queller
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2010       Impact factor: 2.198

3.  The BACHD Rat Model of Huntington Disease Shows Signs of Fronto-Striatal Dysfunction in Two Operant Conditioning Tests of Short-Term Memory.

Authors:  Erik Karl Håkan Clemensson; Laura Emily Clemensson; Olaf Riess; Huu Phuc Nguyen
Journal:  PLoS One       Date:  2017-01-03       Impact factor: 3.240

4.  Reduced caudate nuclei volumes in patients with congenital central hypoventilation syndrome.

Authors:  R Kumar; R Ahdout; P M Macey; M A Woo; C Avedissian; P M Thompson; R M Harper
Journal:  Neuroscience       Date:  2009-07-24       Impact factor: 3.590

5.  Early changes in white matter pathways of the sensorimotor cortex in premanifest Huntington's disease.

Authors:  Eve M Dumas; Simon J A van den Bogaard; Margot E Ruber; Ralf R Reilman; Julie C Stout; David Craufurd; Stephen L Hicks; Chris Kennard; Sarah J Tabrizi; Mark A van Buchem; Jeroen van der Grond; Raymund A C Roos
Journal:  Hum Brain Mapp       Date:  2011-01-24       Impact factor: 5.038

Review 6.  Huntington's disease: the coming of age.

Authors:  Mritunjay Pandey; Usha Rajamma
Journal:  J Genet       Date:  2018-07       Impact factor: 1.166

7.  Abnormal cerebellar volume and corticocerebellar dysfunction in early manifest Huntington's disease.

Authors:  Robert Christian Wolf; Philipp Arthur Thomann; Fabio Sambataro; Nadine Donata Wolf; Nenad Vasic; G Bernhard Landwehrmeyer; Sigurd Dietrich Süßmuth; Michael Orth
Journal:  J Neurol       Date:  2015-01-28       Impact factor: 4.849

8.  Longitudinal task-negative network analyses in preclinical Huntington's disease.

Authors:  Robert Christian Wolf; Fabio Sambataro; Nenad Vasic; Nadine Donata Wolf; Philipp Arthur Thomann; G Bernhard Landwehrmeyer; Michael Orth
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2013-09-27       Impact factor: 5.270

9.  Neural correlates of impaired emotion processing in manifest Huntington's disease.

Authors:  Imis Dogan; Christian Saß; Shahram Mirzazade; Alexandra Kleiman; Cornelius J Werner; Anna Pohl; Johannes Schiefer; Ferdinand Binkofski; Jörg B Schulz; N Jon Shah; Kathrin Reetz
Journal:  Soc Cogn Affect Neurosci       Date:  2013-03-11       Impact factor: 3.436

Review 10.  Magnetic resonance imaging of Huntington's disease: preparing for clinical trials.

Authors:  S Klöppel; S M Henley; N Z Hobbs; R C Wolf; J Kassubek; S J Tabrizi; R S J Frackowiak
Journal:  Neuroscience       Date:  2009-01-29       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.